Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients with NSCLCs Harboring MET Exon 14 Skipping Alterations

Shun Lu,Jian Fang,Xingya Li,Lejie Cao,Jianying Zhou,Qisen Guo,Zongan Liang,Ying Cheng,Liyan Jiang,Nong Yang,Zhigang Han,Jianhua Shi,Yuan Chen,Hua Xu,Helong Zhang,Gongyan Chen,Rui Ma,Sanyuan Sun,Yun Fan,Songhua Fan,Jie Yu,Puhan Lu,Xian Luo,Weiguo Su
DOI: https://doi.org/10.1016/j.jtocrr.2022.100407
2022-01-01
JTO Clinical and Research Reports
Abstract:Introduction: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alterations (MET ex14 positive) at the primary analysis of a phase 2 study. Here, we present the long-term efficacy and safety data of savolitinib, including subgroup analyses.Methods: This multicenter, single-arm, open-label, phase 2 study in the People's Republic of China enrolled MET inhibitor-naive adults with locally advanced or metastatic METex14-positive NSCLC (NCT02897479). Oral savolitinib at a dose of 400 or 600 mg was administered once daily (body weight dependent). The primary objectives of the final analysis were long-term overall survival (OS) and subgroup analyses by previous systemic treatment, NSCLC subtypes, and brain metastases.Results: At the final analysis cutoff date (June 28, 2021), a total of 70 patients were enrolled and receiving savolitinib, and median follow-up was 28.4 (interquartile range: 26.2- 36.3) months. The median OS was 12.5 months (95% confidence interval [CI]: 10.5-21.4 [18-and 24-mo OS rates, 42.1% and 31.5%, respectively]). Median OS in pretreated or treatment-naive patients was 19.4 (95% CI: 10.5-31.3) and 10.9 (95% CI: 7.5-14.0) months, respectively; it was 10.6 months (95% CI: 4.6-14.0) in patients with pulmonary sarcomatoid carcinoma, 17.3 months (95% CI: 10.6-23.6) in other NSCLC subtypes, and 17.7 months (95% CI: 10.5-not evaluable) in patients with brain metastases. No new safety signals emerged with prolonged follow-up and exposure.Conclusions: The updated results further confirm the favorable benefit and acceptable safety of savolitinib in Chinese patients with METex14-positive NSCLC.(c) 2022 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 4.0/).
What problem does this paper attempt to address?